Every Form 4 that Oncotelic Therapeutics Inc (OTLC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OTLC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OTLC filings page.
Fein Seymour Howard reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. granted its CRO/CMO, Seymour Howard Fein, 250 restricted stock units on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, and each preferred share is convertible into 1,000 common shares, contingent on performance and time-based vesting. Vesting requires an uplisting of the common stock to a national securities exchange by June 30, 2027 (or a later Board-approved date) and six months of continued service after the uplisting.
KING STEVEN W reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics granted director Steven W. King 250 restricted stock units (RSUs) on July 10, 2026 at $0.00 per unit. Each RSU is subject to performance and time-based vesting and represents a contingent right to one share of Series A Convertible Preferred Stock, with each such share convertible into 1,000 common shares. The RSUs vest only if the company uplists its common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and he remains in service for six months after any such uplisting; following this grant he holds 250 RSUs directly.
MAIDA ANTHONY E III reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. reported that director and Chief Medical Officer – Translational Medicine Anthony E. Maida III received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026 at no cost. Each RSU settles into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock. The RSUs are subject to performance and time-based vesting, becoming eligible upon an uplisting of the company’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and the executive’s continued service for six months following the uplisting.
Oncotelic Therapeutics CBO Saund Saran received a grant of 1,500 restricted stock units on July 10, 2026. Each RSU represents a contingent right to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, for up to 1,500,000 common shares if fully vested and converted. The RSUs are subject to performance and time-based vesting tied to an uplisting of the company’s common stock to a national securities exchange and continued service requirements.
Shah Amit B. reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics CFO Amit B. Shah received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, which is itself convertible into common stock, if performance and time-based vesting conditions tied to a national-exchange uplisting are satisfied.
Trieu Vuong reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics reports that Chairman and CEO Trieu Vuong received a grant of 2,000 restricted stock units on July 10, 2026. Each RSU can settle into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, subject to performance- and time-based vesting. The RSUs vest only if the company uplists its common stock to a national securities exchange by June 30, 2027 (or a later board-approved date) and Vuong remains in service for six months after uplisting. After these reported holdings, Vuong owns 94,124,319 common shares directly and holds additional shares indirectly, including 6,872,529 through his spouse and 16,780,384 through Autotelic Inc.
Oncotelic Therapeutics, Inc. Chairman and CEO Dr. Vuong Trieu reported an open-market purchase of company stock. On July 1, 2026, he bought 240,000 shares of Common Stock at a price of $0.0431 per share in his individual capacity.
Following this transaction, Dr. Trieu directly owned 94,124,319 shares of Common Stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc., providing a view of both his direct and indirect ownership stakes.
Oncotelic Therapeutics, Inc. director, chairman, CEO and ten percent owner Vuong Trieu reported open-market purchases of a total of 255,000 shares of common stock at $0.045 per share over three days in late June 2026. He bought 65,000 shares on June 22, 75,000 shares on June 23, and 115,000 shares on June 24 in his individual capacity. Following these purchases, his directly held stake rose to 93,884,319 shares. The filing also lists additional indirect holdings of common stock, including 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc. as of June 22.
Oncotelic Therapeutics, Inc. CFO Amit B. Shah bought additional company stock in the open market. On June 22, 2026, he purchased 20,000 shares of common stock at a price of $0.05 per share in his individual capacity. Following this transaction, he directly owns 378,837 shares of Oncotelic common stock.
Oncotelic Therapeutics, Inc. Chairman and CEO Vuong Trieu reported open-market purchases of company common stock. On June 15, 2026, he bought 96,000 shares at $0.05 per share, and on June 17, 2026, he bought 239,759 shares at $0.0446 per share.
After these transactions, his directly held stake is reported as 93,629,319 shares of common stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held through Autotelic Inc., providing a view of both his direct and related-entity ownership.
Oncotelic Therapeutics Chairman and CEO Vuong Trieu reported an award of 4,426 shares of Series A Convertible Preferred Stock on January 22, 2026. The preferred stock is convertible at the holder’s option into 4,426,000 shares of common stock on a one-for-one thousand basis and was issued at a stated price of $0.00 per share as compensation for achieving performance milestones under a Restricted Stock Agreement dated January 21, 2026. Following this grant, Dr. Trieu beneficially owns 8,491 shares of the Series A Convertible Preferred Stock directly.
Oncotelic Therapeutics, Inc. (OTLC) disclosed an insider equity award for Chairman and CEO Vuong Trieu, who is also a director and 10% owner. A Form 4 reports that he received 4,065 shares of Series A Convertible Preferred Stock on 11/17/2025, classified as an acquisition. Each preferred share is convertible at the holder’s option into common stock on a one-for-one thousand basis, representing 4,065,000 underlying common shares. The preferred shares were issued to Dr. Trieu as compensation tied to performance milestones under a Restricted Stock Agreement dated November 17, 2025, and are held directly.